Table 3

Association between variables and pain trajectories from a multivariable multinomial logistic regression using 50 multiple imputed datasets (n=851)

VariableRelative risk ratio (95% CI)
Improved versus Consistently lowConsistently high versus consistently lowConsistently high versus improved
Baseline
Gender (base: female)
 Male0.5 (0.3 to 0.9)*0.7 (0.4 to 1.4)1.5 (0.9 to 2.5)
Age at onset, per year1.1 (0.99 to 1.1)1.1 (1.1 to 1.2)*1.1 (1.0 to 1.2)*
PGA, per cm1.1 (0.9 to 1.3)1.1 (0.9 to 1.3)1.0 (0.8 to 1.2)
Disease duration, per month1.02 (1.0 to 1.04)*1.03 (1.0 to 1.1)*1.0 (0.99 to 1.0)
AJC, per joint0.9 (0.8 to 1.1)0.95 (0.8 to 1.1)1.0 (0.9 to 1.1)
PGE, per cm1.3 (1.0 to 1.5)*1.4 (1.1 to 1.7)*1.1 (0.9 to 1.3)
CHAQ, per 0.1251.1 (0.96 to 1.1)1.2 (1.0 to 1.3)*1.1 (1.0 to 1.2)*
Pain, per cm3.2 (2.5 to 4.1)*3.1 (2.4 to 4.0)*1.0 (0.8 to 1.1)
MFQ, per 5%1.3 (0.7 to 2.5)1.3 (0.6 to 2.8)1.0 (0.6 to 1.7)
Early change
DMARDs in 1st year (base: no)
 Yes1.2 (0.7 to 2.1)0.8 (0.4 to 1.5)0.6 (0.4 to 1.1)*
Biologics in 1st year (base: no)
 Yes2.3 (0.8 to 6.1)3.0 (1.0 to 8.8)*1.3 (0.7 to 2.6)
Steroids in 1st year (base: no)
 Yes1.0 (0.5 to 1.9)1.4 (0.7 to 3.1)1.4 (0.8 to 2.6)
Change in AJC in 1st 6 months, per joint increase0.9 (0.8 to 1.1)1.0 (0.8 to 1.1)1.0 (0.9 to 1.1)
Change in PGA in 1st 6 months, per cm increase1.2 (0.9 to 1.4)1.1 (0.9 to 1.4)1.0 (0.8 to 1.2)
Change in PGE in 1st 6 months, per cm increase1.3 (1.1 to 1.5)*1.4 (1.2 to 1.7)*1.1 (1.0 to 1.3)*
Change in CHAQ in 1st year, per 0.125 increase1.1 (1.01 to 1.2)*1.2 (1.1 to 1.3)*1.1 (1.0 to 1.1)*
Change pain in 1st year, per cm increase1.4 (1.2 to 1.7)*1.7 (1.4 to 2.1)*1.2 (1.1 to 1.3)*
  • *P≤0.05.

  • CHAQ, Childhood Health Assessment Questionnaire; DMARDs, disease-modifying antirheumatic drugs; MFQ, Moods and Feelings Questionnaire; PGA, Physician’s Global Assessment; PGE, parent’s/patient’s general evaluation.